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Trichloroethylene (TCE) is a chlorinated organic solvent widely used as a feedstock material in chemical manufacturing, as well as in various industrial applications including dry cleaning and vapor degreasing. Since the beginning of its widespread production dating back to the 1920s (National Industrial Chemicals Notification and Assessment Scheme [NICNAS], 2000) , it has been recognized as an occupational and environmental health concern due to high human exposure and its potential to be a health hazard (National Research Council [NRC], 2006) . The number of workers in occupations with likely TCE exposure has declined in the developed countries in the past 20 years (von Grote et al., 2003) . Still, TCE is one of the major contaminants found in the Superfund hazardous waste sites across the United States (U.S. Environmental Protection Agency [EPA] , 2011) and is ranked 16th on the Substance Priority List by the U.S. Agency for Toxic Substances and Disease Registry (ATSDR, 2011) .
TCE poses a potential human health hazard for noncancer toxicity to the central nervous system, kidney, liver, immune system, male reproductive system, and developing fetus . In addition, TCE is classified as carcinogenic to humans by IARC (Guha et al., 2012) and the U.S. Environmental Protection Agency (EPA) (2011) based on the evidence in humans of a causal relationship between kidney cancer and exposure to TCE. Positive, although less consistent, associations with TCE were reported studies of liver cancer and non-Hodgkin lymphoma (Scott and Jinot, 2011) .
Liver toxicity and carcinogenicity remain largely unresolved with regard to the human health hazard of TCE . There is clear evidence that TCE is a hepatic carcinogen in rodents (National Toxicology Program, 1990; Anna et al., 1994) ; however, the relationship between occupational TCE exposure and risk of liver cancer in humans is still inconclusive, given that epidemiologic studies noted both positive and negative associations (Vlaanderen et al., 2013; Radican et al., 2008) . A recent metaanalysis reported a meta-relative risk of 1.3 (95% confidence interval [CI] 1.1-1.6) for overall TCE exposure and liver cancer based on 9 human cohorts (Scott and Jinot, 2011) .
There are also uncertainties regarding the potential mode of action for TCE tumorigenesis in liver . TCE is metabolized through both cytochrome P-450 (P450)-dependent oxidation and glutathione conjugation to form a number of toxic species . Metabolites of the oxidative pathway, trichloroacetic (TCA) and dichloroacetic (DCA) acids are widely considered to be primary mediators of toxicity and carcinogenicity of TCE in the liver via peroxisome proliferatoractivated receptor (PPARα) activation. The latter is one of the most studied mechanisms of action for TCE-induced hepatic cancer in rodents (Klaunig et al., 2003; Keshava and Caldwell, 2006) . Studies in vitro demonstrated that human PPARα is activated by TCA and DCA, but relatively inactive to TCE itself (Maloney and Waxman, 1999; Zhou and Waxman, 1998) . In addition, human hepatocytes transfected with mouse PPARα displayed increased expression of PPARα, and elevated peroxisome proliferator response elementreporter activity when treated with TCA and DCA (Walgren et al., 2000) .
Although it is widely presumed that tissuespecific formation of TCE metabolites is one of the critical determinants for the plethora of its adverse health effects, most studies of TCE toxicokinetics were performed in blood. Few studies evaluated TCE metabolism in tissues; however, one study in rats did not find a dose-response relationship in formation of TCE metabolites in liver and kidney (Lash et al., 2006) . Thus, a hypothesis was tested that formation of oxidative metabolites of TCE in mouse liver is associated with hepaticspecific toxicity by determining the quantitative relationship between strain-, dose-, and time-dependent formation of TCA and DCA in serum and liver and various hepatic toxicity phenotypes in a panel of mouse inbred strains.
MATERIALS AND METHODS

Animals and Treatments
Male mice (aged 6-7 wk) were purchased from the Jackson Laboratory (Bar Harbor, ME) and housed in polycarbonate cages on SaniChips (P. J. Murphy Forest Products Corp., Montville, NJ) irradiated hardwood bedding. Animals were fed an NTP-2000 (Zeigler Brothers, Inc., Gardners, PA) wafer diet and water ad libitum on a 12-h light-dark cycle. All studies were approved by the UNC Institutional Animal Care and Use Committee.
Two study designs were utilized in this investigation. First, a subacute study was performed where vehicle (10 ml/kg, 5% Alkamuls EL-620 in saline) or TCE (600 mg/kg/d, in vehicle) was administered by gavage to mice from 7 inbred strains (129S1/SvImJ, A/J, BTBR T+tf/J, C57BL/6J, CAST/EiJ, NOD/ShiLtJ, and NZW/LacJ) for 5 consecutive days. These strains were selected to maximize interstrain differences in metabolism of TCE based on the previous study of TCE metabolism in a panel of inbred strains (Bradford et al., 2011) time and strain on TCE metabolite concentrations, which support the sample size used in this study . Second, based on the data from the subacute study, two inbred strains (C57BL/6J and NZW/LacJ) were selected that represented widely varying degrees of formation of oxidative metabolites of TCE for a subsequent subchronic study. Specifically, animals of each strain were randomly assigned to one of 3 groups (5% Alkamuls EL-620 in saline vehicle, 100, or 400 mg/kg/d TCE) and were dosed by oral gavage daily for 5 d, 2 wk, or 4 wk (the latter two were dosed for 5 d/wk).
In all studies, mice were given drinking water containing 0.2 g/L of 5-bromo-2 -deoxyuridine (BrdU) for 72 h prior to sacrifice. Blood, tissues (liver, kidneys, etc.) , and a section of a duodenum were collected 2 h after the last treatment. The timing of sacrifice was selected based on the toxicokinetic studies of TCE in the mouse (Bradford et al., 2011; Kim et al., 2009b) , showing that concentrations of both oxidative and glutathione conjugation metabolites of TCE peak approximately 2 h after dosing. Blood was drawn from vena cava and centrifuged to prepare serum using Z-gel tubes (Sarstedt, Germany) according to the manufacturer's instructions. Body and organ weights were recorded. Liver and duodenum sections were fixed in neutral buffered formalin for 24 h, and the remainder of the hepatic tissue was frozen in liquid nitrogen. All serum and tissue samples were stored at −80
• C until analyzed.
Quantification of TCE Metabolites
Concentrations of TCA, DCA, S-(1,2-dichlorovinyl)-L-cysteine (DCVC), and S-(1,2-dichlorovinyl) glutathione (DCVG) in serum and liver were determined using high-performance liquid chromatography-electron spray ionization with tandem mass spectroscopy (HPLC-ESI-MS/MS) as detailed elsewhere (Kim et al., 2009a) with slight modifications. Quantification of trichloroethanol (TCOH) in liver was performed using the method of (Song and Ho, 2003) . The configuration of the instruments was identical to that in the already-mentioned references, but the extraction methods were optimized for each tissue (liver or serum) and metabolite as follows.
TCA and DCA Serum (50 μl) was mixed with 100 μl internal standards (difluoroacetic acid [DFA] and trifluoroacetic acid [TFA] , 50 nmol/ml each). Serum proteins were then removed by filter-centrifugation (Microcon YM-10; Millipore, Billerica, MA) at 14,000 × g for 1 hr. Liver samples (100 mg) were homogenized in 500 μl 0.01 M phospharebuffered saline (PBS; pH 7.4) with 20 μl internal standards (DFA and TFA, 20 nmol/ml each) using Tissuelyser (Qiagen, Valencia, CA) for 1 min. The homogenates were filtercentrifuged (Amicon Ultra Centrifugal Filters 10K; Millipore) at 14,000 × g for 1 h. After the filtrate was acidified with 100 μl 3% (v/v) sulfuric acid, 2 ml diethyl ether was added and solutions were vortexed vigorously for 1 min. The upper ether layer was transferred to another vial, reduced in volume to less than 300 μl under a continuous stream of N 2 , then transferred to a glass vial insert containing 5 μl double-distilled water and dried completely. The residue was reconstituted in 20 μl HPLC mobile phase consisting of 70% acetonitrile, 30% 1 mM ammonium citrate in double-distilled water. The lower limits of quantification (LLOQ) were 0.04 nmol/ml in serum and 0.1 nmol/g in liver for DCA, and 5 nmol/ml in serum and 8 nmol/g in liver for TCA.
DCVG and DCVC Serum (50 μl) was mixed with 100 μl internal standard solution ([ 13 C 2 , 15 N]DCVG and [ 13 C 3 , 15 N]DCVC, 5 nmol/mL each). Serum proteins were then removed by filter-centrifugation (Microcon YM-10; Millipore) at 14,000 × g for 1 h. Liver tissue (100 mg) was homogenized in 500 μl of 0.01 M PBS (pH 7.4) with 20 μl internal standards ([ 13 C 2 , 15 N]DCVG and [ 13 C 3 , 15 N]DCVC, 25 nmol/ml each) using Tissuelyser (Qiagen) for 1 min. The homogenates were filtercentrifuged (Amicon Ultra Centrifugal Filters 10K; Millipore) at 14,000 × g for 1 h. From each prepared sample, DCVG and DCVC were extracted using a solid-phase extraction cartridge (StrataTM X-AW, 30 mg, 96-well plate; Phenomenex, Torrance, CA). The cartridges were conditioned with 300 μl methanol, followed by equilibration with 300 μl water. Samples were loaded, washed with 300 μl water, and eluted with 250 μl basic methanol (pH adjusted to 10.8 by 29.1% NH 4 OH). The final eluent was collected in 300-μl glass vial inserts and dried in a SpeedVac Concentrator before reconstitution with 20 μl 4:1 water/methanol containing 0.1% acetic acid. The LLOQ were 0.5 pmol/ml in serum and 2 pmol/g in liver for DCVG, and 1 pmol/ml in serum and 20 pmol/g in liver for DCVC.
TCOH Liver tissue (30 mg) was homogenized in 500 μl acetate buffer (pH 4.6) with 1000 units β-glucuronidase (Sigma [G0751], St. Louis, MO) using Tissuelyser (Qiagen) for 1 min, followed by overnight incubation at 37
• C. After centrifugation at 14,000 × g for 5 min, the supernatant was transferred to a new tube, then mixed with 20 μl internal standard (DCA, 10 mM in methanol) and 550 μl water/0.1 M sulfuric acid/methanol (6:5:1). The mixture was heated at 70
• C for 20 min. After cooling to room temperature, 2.5 ml hexane was added, and the mixture was vortexed for 10 min and centrifuged at 2500 × g for 2 min. The upper layer was concentrated under a stream of N 2 to less than 20 μl and used for gas chromatography-mass spectroscopy (GC-MS) analysis as detailed in Song and Ho (2003) . The LLOQ was 5 nmol/g in liver.
Gene Expression Analysis by Real-Time PCR
Total RNA was isolated from liver samples using an RNeasy kit (Qiagen) according to the manufacturer's instructions. RNA concentration and quality were determined using an ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE) and Agilent 2000 Bioanalyser, respectively. Total RNA was reverse transcribed using random primers and the high-capacity complementary DNA archive kit (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. The following gene expression assays (Applied Biosystems) were used for quantitative real-time polymerase chain reaction (PCR): PPARα (Mm00440939_m1); palmitoyl acyl-Coenzyme A oxidase 1 (Acox1, Mm01246831_m1); cytochrome P-450, family 4, subfamily a, polypeptide 10 (Cyp4a10, Mm01188913_g1); and beta glucuronidase (Gusb, Mm00446953_m1). Reactions were performed in a 96-well plate, and all samples were plated in duplicate using a LightCycler 480 instrument (Roche Applied Science, Indianapolis, IN). The cycle threshold (Ct) for each sample was determined from the linear region of the amplification plot. The Ct values for all genes relative to the control gene Gusb were determined. The Ct were calculated using treated group means relative to strainmatched control group means. Fold change data were calculated from the Ct values.
Protein Level Measurements
Proteins were extracted from 20 mg frozen liver samples using T-PER Tissue Protein Extraction Reagent (Pierce Biotechnology, Rockford, IL) and Halt Protease Inhibitor Cocktail (Pierce Biotechnology) according to the manufacturer's instructions. Protein concentration was measured using Pierce BCA Protein Assay Kit (Pierce Biotechnology) and a DTX 880 Multimode Detector (Beckman Coulter, Brea, CA). Extracts containing 30 μg protein were resolved on 12% polyacrylamide sodium dodecyl sulfate-containing gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked in Odyssey Blocking Buffer (LI-COR, Lincoln, NE) and probed with 1:5000 diluted anti-cytochrome P-450 2e1 antibody (Abcam, Cambridge, MA), anti-Aldh2 antibody (Abcam), or anti-Adh antibody (Abcam) overnight at 4
• C. Blots were washed in 0.1% Tween20 in 0.01 M PBS, incubated with 1:20,000 IRDye 680LT donkey anti-rabbit immunoglobulin G (IgG; LI-COR), and detected using an Odyssey Infrared Imaging System (LI-COR). Equal protein loading was confirmed by total protein staining with 0.1% (w/v) naphthol blue black in 7% (v/v) acetic acid in water for 10 min. The 
Statistical Analysis
The significance of interstrain effect on metabolism was assessed by analysis of variance (ANOVA) modeling. Given the small sample size, the exact permutation test was used to determine significant differences between control and TCE-treated groups (α = .05). The Spearman (rank) correlation analysis across all variables was conducted to account for the difference in scale of the variables. In correlation analyses, false discovery rate correction (Storey and Tibshirani, 2003) was applied to all p values to correct for multiple comparisons. The resultant significant (<.1) q values are reported in the Supplemental Tables. All statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, NC).
Data Availability
Individual animal-level data for all quantitative endpoints are available publicly at the Mouse Phenome Database (http://phenome. jax.org; accession ID: Rusyn6).
RESULTS
Subacute (5-Day) Studies of Strain-Dependent Effects of TCE in Mouse Liver
Serum and liver levels of TCE metabolites from P450-mediated oxidation (TCA, DCA, TCOH) and glutathione conjugation (DCVC and DCVG) were determined in seven mouse inbred strains (Figure 1 ). Mice were treated for 5 d by oral gavage of 600 mg/kg of TCE in aqueous vehicle. Across all strains, serum levels ( Figure 1 , left panel) of TCA were on average 1000-fold greater than those for DCA, and amounts of DCA were about 100-fold higher than those of either DCVC or DCVG. Higher levels of TCA (approximately twofold) and DCA (approximately 10-fold) were found in liver (Figure 1 , right panel) than in serum, but the relative ratio of TCA to DCA was similar. The levels of hepatic TCOH, also a major TCE metabolite, were comparable to those of TCA. Levels of DCVG were much higher in liver than serum (about 100-fold) and only about 10-fold lower than those of DCA. A marked difference was observed between concentrations of DCVG and DCVC in liver. While the amounts of DCVG and DCVC in serum were comparable (<2-fold difference), the concentration of DCVG in hepatic tissue was at least 50-to 100-fold higher than that of DCVC, which was below the LLOQ in most samples. A significant strain effect was found in both serum and liver for every metabolite examined (TCA, DCA, TCOH, DCVG, and DCVC).
The relationships between TCE metabolites in either serum or liver (Supplemental Table 1 ) were examined. In serum, no significant correlations among five metabolites were noted. In liver, levels of TCA and DCA were significantly correlated (ρ = 0.74, q = 0.001). Although both TCA and TCOH are major oxidative metabolites, no correlation was found between their levels in liver. Intertissue (liver vs. serum) correlation of TCE metabolites was also evaluated. Significant correlation was noted between liver and serum levels for TCA (ρ = 0.62, q = 0.020), serum TCA and hepatic DCA (ρ = 0.78, q = 0.001), and serum DCVC and liver DCVG (ρ = 0.67, q = 0.017).
To determine whether interstrain differences in TCE metabolism may be due to strain-dependent variability in expression of CYP2E1, the levels of liver CYP2E1 protein were measured in vehicle-and TCE-treated animals (Figure 2) . A significant strain effect was found in baseline liver CYP2E1 levels. However, treatment with TCE was without effect on hepatic CYP2E1 across all strains. Interestingly, the background hepatic levels of CYP2E1 were not correlated (ρ = 0.74, p = 0.055) with the amount of TCA in liver of TCE-treated animals.
Liver size (relative to body weight) and hepatocellular proliferation were examined in vehicle-and TCE-treated mice ( Figures 3A and  3B ). Significant effects of subacute treatment were observed with TCE on liver enlargement in 129S1/SvlmJ, NOD/ShiLtJ, and BTBR FIGURE 1. Interstrain variability in TCE metabolism in the mouse in a subacute study. Serum (A-D) and liver (E-I) levels of metabolites were assessed 2 h following the last of 5 daily doses (600 mg/kg) of TCE. Box and whisker plots are shown (+, mean; line, median; box, interquartile range; whiskers, min to max). When box is shown, four animals per group were available. Otherwise, there were three animals per group. T+tf/J, and on hepatocyte proliferation in NOD/ShiLtJ, BTBR T+tf/J, and NZW/LacJ strains. Because peroxisome proliferation was suggested as contributing to hepatomegaly in rodents (Marsman et al., 1988) , expression of Cyp4a10 and Acox1, marker genes for this mechanistic event, were evaluated in mouse liver. Expression of the transcription factor Ppara was not affected by TCE (data not shown); however, expression of Cyp4a10 and Acox1 was markedly elevated in all strains, except for CAST/EiJ ( Figures 3C and 3D) , with TCE-induced effect being greater for Cyp4a10 than for Acox1.
TCE METABOLISM AND LIVER EFFECTS
Because interstrain differences in both TCE metabolism and liver effects were observed in this study, the associations were examined among these endpoints in liver (Supplemental Table 2 ). Levels of TCA and DCA were strongly correlated with expression of Acox1 and Cyp4a10 (Figures 4A and 4B) . However, neither the expression of Acox1 and Cyp4a10 nor the level of TCA was correlated with hepatocellular proliferation ( Figures 4C and 4D , respectively).
Subchronic (up to 4 Weeks) Studies of Strain-Dependent Effects of TCE in Mouse Liver
Based on the differences in TCE metabolism observed in the subacute (5-d) TCE exposure studies, C57BL/6J and NZW/LacJ strains were selected to further test our hypothesis that interstrain differences in amounts of oxidative metabolites of TCE in liver are associated with hepatic-specific toxicity. In these studies, time-dependent (1, 2, and 4 wk) and dose-dependent (100 and 400 mg/kg/d, ig) effects of TCE were examined.
As expected, the difference in TCE metabolism between two strains was also observed at lower doses and in longer term studies ( Figure 5 ). Serum and liver levels of TCA and DCA were higher in NZW/LacJ mice, and hepatic levels of DCVG were higher in C57BL/6J mice. Similar to the findings in the subacute study, levels of TCA and TCOH in liver were 100-to 1000-fold greater than those of 22 H. S. YOO ET AL. FIGURE 3. Interstrain differences in liver toxicity of TCE in a subacute study. Liver to body weight ratios (A), percent BrDU-positive hepatocyte nuclei (B), and liver expression of peroxisome proliferation marker genes Acox1 (C) and CYP4A10 (D) were evaluated in mice treated with vehicle (white) or TCE (black; 600 mg/kg) for 5 d. Box and whiskers plots are shown (+, mean; line, median; box, interquartile range; whiskers, min to max). When box is shown, four animals per group were available. Otherwise, there were three animals per group. Asterisk denotes a significant difference (p < .05) compared to vehicle-treated group within same strain.
DCA, and levels of DCA were 10-to 100-fold higher than those of DCVG. Levels of DCVC in serum and liver were below the LLOQ. Amounts of all measured TCE metabolites in hepatic tissue and serum generally trended downward over time. Specifically, the levels of TCA in serum and liver decreased over time in both strains, while the levels of TCOH in hepatic tissue decreased over time only in C57BL/6J strain. Similarly, the level of DCVG in liver was highest after 5 d of treatment.
Among TCE metabolites that were measured in this study, serum and liver levels of TCA and DCA were highly correlated (q < 0.001) across all animals in the study (Supplemental Table 3 ). Hepatic levels of TCOH exhibited similar strong correlation with levels of TCA and DCA in either serum or liver. No marked correlation was found among levels of DCVG in liver and other TCE metabolites.
To determine whether strain-dependent changes in TCE-metabolizing enzymes could account for the observed decrease in metabolite formation over time, levels of CYP2E1, ALDH2, and ADH proteins were measured in liver, and it was found that expression of these enzymes was not markedly affected by TCE treatment (Figure 6 ).
The effects of subchronic treatment were also examined with TCE on liver weight and marker genes of hepatocellular proliferation and peroxisome proliferator expression. Even though the amount of oxidative metabolites of TCE trended downward over time, the increased liver to body weight ratio was still observed in mice treated for 2 wk or 4 wk in a strain-dependent manner. In the case of hepatocellular proliferation, most prominent effects were observed at the 4 wk time-point ( Figures 7A and 7B) . Histopathological evaluation of hepatic sections revealed concordant elevation in relative size of hepatocytes, as well as hemosiderin deposits in the highdose 4-wk treatment groups of both strains (Supplemental Figure 1) . A prominent effect of TCE on hepatic peroxisome proliferation was noted in the subchronic study. Although TCE did not affect expression of Ppara (data not shown), expression of Acox1 and Cyp4a10 was strongly induced in a dose-dependent manner in both strains of mice treated with TCE for 5 d (Figures 7C and 7D) . Interestingly, the magnitude of upregulation of Acox1 and Cyp4a10 by TCE diminished over time. In the 2-and 4-wk treatment groups, either there was no marked difference in gene expression between vehicle and TCE-treated animals, or differences were less prominent.
Similar to the result of the subacute study, the levels of TCA and DCA were significantly correlated with Acox1 and Cyp4a10 expression in liver regardless of TCE dose or treatment duration ( Figures 8A and 8B ). The Cyp4a10 expression was significantly correlated with liver-to-body weight ratio (ρ = 0.68, q < 0.001, Figure 8C) ; however, hepatocellular proliferation did not correlate with other variables ( Figure 8D and Supplemental Table 4 ).
DISCUSSION
The challenge of addressing variability in susceptibility to environmental exposures is frequently one of the most contentious issues in human health assessments. Because of the heterogeneity of the human population, it is generally expected that there will be a broad range of toxicokinetic and toxicodynamic responses to chemicals or drugs (Zeise et al., 2013) . Traditionally, interindividual differences in toxicokinetics are accounted for by default assumptions, and only in rare cases are they based on human toxicokinetic data. Seldom is there sufficient data to evaluate the extent of variability in toxicodynamics.
Because TCE metabolism to form chloroacetic acids and GSH-conjugates is widely accepted as the mechanism leading to toxicity in various organs (Lash et al., 2001) , the 24 H. S. YOO ET AL. FIGURE 5. Time-course analysis of TCE metabolism in C57BL/6J and NZW/LacJ mice in a subchronic study. Serum (A) and liver (B) levels of metabolites were assessed 2 h following the last dose after 1, 2, or 4 wk (100 or 400 mg/kg/d) of TCE. Box and whiskers plots are shown (+, mean; line, median; box, interquartile range; whiskers, min to max). Light gray, 100-mg/kg/d groups; dark gray, 400-mg/kg/d groups. When box is shown, four animals per group were available. Otherwise, there were three animals per group. Asterisks denote a significant (p < .05) difference as compared to the group dosed with 100 mg/kg/d (same strain and time point); #, the 5-d treatment group (same strain and dose); and &, the values in C57BL/6J strain (same dose and time point).
interplay between toxicokinetics and toxicodynamics is a critically important consideration in the evaluation of human health hazard of TCE. Some understanding of the human population variability in toxicokinetics of TCE is available based on limited data from clinical studies and Bayesian modeling (Chiu et al., 2009) . Metabolism of TCE across species (e.g., rodents and humans) is qualitatively similar , and thus interspecies and interindividual variability in TCE toxicity is likely due to the variability in TCE metabolism Green, 1990) . TCE toxicity is also dose dependent, which suggests a link between toxicokinetics and toxicodynamics . It is yet to be experimentally demonstrated, however, that interindividual variability in TCE metabolism, not exposure (i.e., dose), will result in quantitative differences in its toxicity. In this regard, an examination of the relationship between the variability of metabolism and variability in toxicity may shed light on our understanding of human health hazard of TCE. Therefore, the purpose of this study was to use a population-based approach to test the hypothesis that TCE-induced toxicity in liver is associated with the hepatic-specific formation of oxidative TCE metabolites.
Previously, Bradford et al. (2011) demonstrated that both oxidative metabolism and GSH conjugation of TCE vary considerably among inbred mouse strains, and that such variability was associated with strain-specific differences in gene expression in mouse liver. While these results allowed for a quantitative evaluation of the relationship between metabolism TCE METABOLISM AND LIVER EFFECTS 25 FIGURE 6. The effect of a subchronic treatment with TCE on liver CYP2E1 (A), ALDH2 (B), and ADH (C) protein levels in C57BL/6J and NZW/LacJ mice. Box and whiskers plots are shown (+, mean; line, median; box, interquartile range; whiskers, min to max). Thickness of the line corresponds to the vehicle, 100-, and 400-mg/kg/d groups. There were three animals per group.
and TCE-induced gene expression in the liver, the focus of the study was on toxicokinetic profiling over a 24-h time period and use of one high dose of TCE (2.1 g/kg, ig). To further explore the time and dose relationships between TCE metabolism and toxicity in the context of interstrain variability, a series of studies was conducted that aimed to quantitate levels of TCE metabolites in serum and liver. Cell proliferation and peroxisome proliferation, two widely accepted hepatotoxic phenotypes reflective of the major mechanistic events considered to play a role in liver carcinogenesis of TCE in rodents, were also evaluated .
The first important and novel outcome of this study is quantitative data on a broad range of metabolites produced via oxidative metabolism and GSH conjugation of TCE in serum and liver in the context of interstrain variability in TCE metabolism. While many published reports provide quantitative information on serum levels of TCA along with a few reports of DCA after treatment with TCE in rodents and humans, little information exists on the formation of these metabolites in the liver. Similar to our findings in the single-dose studies in mouse serum (Bradford et al., 2011; Kim et al., 2009b) , there are up to five orders of magnitude difference in the relative flux of TCE through CYP450-dependent oxidation (primarily TCA) compared to GSH conjugation. The similarities in the levels of TCE metabolites formed through oxidation and GSH conjugation in this and our previous studies confirm that GSH conjugation of TCE is a minor pathway in mice, regardless of the dose or duration of treatment.
In the mouse liver, TCA was also the predominant metabolite formed (approximately two orders of magnitude greater than DCA); however, while the difference in relative flux of TCE through CYP450-dependent oxidation compared to GSH conjugation was still large, it was smaller than that in serum, approximately three orders of magnitude. In rat liver, TCA and TCOH are also predominant TCE metabolites and there is approximately 100-fold difference between CYP450-dependent oxidative metabolism and GSH-conjugation (Lash et al., 2006) . TCE metabolism by CYP450-dependent pathway is known to occur at a faster rate in mice than in rats , and our data are in agreement with these observations. Serum levels of TCA and DCA were not correlated with each other, which is consistent with our previous study (Kim et al., 2009b) that postulated that DCA formation is not occurring exclusively from TCA. However, liver levels of TCA and DCA did correlate significantly, which supports a hypothesis that TCA is the major precursor for the formation of DCA in this organ (Ketcha et al., 1996) . A detailed liver toxicokinetic study of oxidative metabolites of 26 H. S. YOO ET AL. FIGURE 7. Differences in liver toxicity of TCE in C57BL/6J and NZW/LacJ mice in a subchronic study. Liver to body weight ratios (A), percent BrDU-positive hepatocyte nuclei (B), and liver expression of peroxisome proliferation marker genes Acox1 (C) and CYP4A10 (D) were evaluated in mice treated with TCE (100 or 400 mg/kg) for 1, 2, or 4 wk. Box and whiskers plots are shown (+, mean; line, median; box, interquartile range; whiskers, min to max). White, vehicle-treated groups; light gray, 100-mg/kg/d groups; dark gray, 400-mg/kg/d groups. When box is shown, four animals per group were available. Otherwise, there were three animals per group. Asterisk denotes a significant (p < .05) difference as compared to vehicle-treated group (same strain and time point).
TCE may be necessary to further characterize the metabolic fate of TCA and DCA.
Our finding that the concentration of DCVG in liver was much higher than that in serum and higher than the concentration of DCVC in either serum or liver further demonstrates that TCE conjugation with GSH to form DCVG occurs predominantly in the liver . Given that DCVG is rapidly excreted into the bile (van Bladeren, 2000) , the relative flux of TCE through GSH conjugation in the liver may be even greater than that observed in our study. As Lash et al. (1999) suggested that GSH conjugation may be much greater in humans than in rodents, careful estimation of the biliary excretion of GSH conjugates of TCE may be needed to completely understand the kinetics of this metabolic pathway.
Based on the levels of TCA and DCA observed in the subacute study (Figure 1) , two strains were chosen, C57BL/6J and NZW/LacJ, which represent low or high levels of CYP450-dependent oxidation of TCE, respectively. Time-course analysis of TCE metabolites in liver showed a decreasing trend of TCA and TCOH concentration, especially in the highdose (400 mg/kg/d) group. Previous studies of TCE metabolism showed that under conditions of acute exposure in mice, the induction of the monooxygenase system resulted in greater liver metabolism of TCE (Dekant et al., 1986) , and no apparent saturation of metabolism was observed . However, saturation of TCE metabolism does occur in rat liver at high doses Dekant et al., 1986) . A long-term study with TCE in rats and mice demonstrated that daily dosing for 180 d did not induce the overall metabolism of TCE, but doubled the urinary excretion of TCA .
Time-dependent change in kinetics may be explained by either auto-induction (Chaudhry et al., 2010) or depletion of co-substrates such as NADPH, NADH, and NAD + (Lipscomb et al., 1996) . Auto-induction may not explain our findings because CYP2E1, ALDH2, and ADH, major enzymes involved in oxidative metabolism of TCE, were not markedly affected by TCE dose or by duration of exposure. In addition, it is possible that a decrease in TCE metabolism may be due to insufficient availability of co-substrates that are affected not only by the extent of metabolism, but also by the redox status of the liver. Oxidative stress, as a secondary event that follows cytotoxicity and peroxisome proliferation in the liver, is one such mechanistic event. Several studies that examined TCA-and DCA-induced hepatic oxidative stress demonstrated small, albeit significant, increases in lipid peroxidation and oxidative DNA damage Parrish et al., 1996) . While it is conceivable that time-dependent decrease in TCE metabolism observed herein may plausibly result from saturation of co-substrate supply or from oxidative stress, these mechanisms need further study.
The second important and novel outcome of our work is the investigation of the quantitative relationships among TCE metabolite levels and liver toxicity phenotypes. Because significant interstrain variability was observed in TCE metabolism and liver toxicity, this study offers a unique opportunity to provide a scientific datadriven rationale for some of the major assumptions in human health assessment of TCE and other chlorinated solvents. Specifically, major metabolizing enzymes responsible for oxidative biotransformation of TCE, as well as markers of cell proliferation and peroxisome proliferation in liver, were determined.
Inter-and intraspecies differences in oxidative metabolism of TCE have been examined in relation to expression levels of key xenobiotic metabolism enzymes, primarily CYP2E1 . A correlation was observed between amounts of TCA produced in liver and a baseline CYP2E1 protein level across strains. This finding may be attributable to the previously reported observation that not only is CYP2E1 involved in the first step of TCE oxidation, but CYP2E1 also catalyzes the transformation of TCOH to TCA (Stenner et al., 1997) . CYP2E1 is not the only CYP450 enzyme that may act on TCE. For example, liver CYP2E1 content was found to be similar in rats and mice (Nakajima et al., 1993) even though major differences in TCE metabolism are known to exist between mice and rats. Human CYP1A1/2, CYP2A6, and CYP3A4 are also known to oxidize TCE, with CYP1A2 being the major alternative to CYP2E1 .
A recent study using a mouse model of the human population showed that TCE metabolism was strongly associated with induction of PPARα-mediated lipid and nucleic acid metabolism pathways in mouse liver regardless of the genetic background (Bradford et al., 2011) . Data showed that under conditions of subacute and subchronic treatment with TCE, significant upregulation of Acox1 and Cyp4a10 expression occurred in six out of seven strains and the extent of gene expression was correlated with the liver levels of TCA and DCA. Strong correlation between TCA and DCA levels in liver makes it difficult to interpret their relative contributions to the induction of peroxisome proliferation response. However, DCA is widely regarded as a weaker ligand for PPARα activation compared to TCA (Corton, 2008) , and the amount of DCA detected in this study in the liver is orders of magnitude lower than that of TCA.
Similar to an observed time-dependent decrease in TCE metabolite formation, the expression levels in Acox1 and CYP4A10 decreased over time in the subchronic study, which indicates a close association between peroxisome proliferation and oxidative metabolism of TCE. Contrary to the reduction in oxidative metabolism and peroxisome proliferation over time, liver enlargement and hepatocellular proliferation effects were most prominent in mice treated with TCE for 4 wk. Neither TCA nor DCA in liver was correlated with hepatocellular proliferation in the subchronic study, which may suggest that multiple metabolites or pathways are likely to be involved in hepatic toxicity due to TCE .
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